Tandem Diabetes Care

Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006, and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Tandem Diabetes Care reports robust sales growth and strategic innovations

Tandem Diabetes Care's strong financial performance, innovative product portfolio, and global market expansion efforts position it for continued growth and competitiveness.
While facing short-term challenges like seasonal EBITDA fluctuations and acquisition-related headwinds, Tandem's strategic focus on new product launches and market awareness presents opportunities for long-term success.
The company's emphasis on technology advancements, clinical initiatives, and leadership continuity underscores its commitment to driving innovation and meeting customer needs in the insulin therapy market.
With a clear roadmap for 2023, including revenue projections, margin expectations, and product development plans, Tandem is poised to navigate challenges and capitalize on growth opportunities in the evolving healthcare landscape.

Tandem Diabetes Care reports strong Q1 performance amidst competitive challenges

Tandem Diabetes Care's Q1 2023 earnings call showcased strong performance driven by product success and customer loyalty, despite challenges in international revenue and competitive landscape noise.
The company's focus on innovation, cost management, and product enhancements positions it well for long-term growth and market expansion, with opportunities in Libre integration and upcoming product launches.
While facing short-term challenges in Q2 revenue and margins, Tandem Diabetes Care remains confident in achieving its objectives through prudent cost management and commitment to product excellence.

Tandem Diabetes Care exceeds Q2 targets, eyes sustainable growth

Tandem Diabetes Care (TNDM) showcased strong Q2 performance, with a focus on sustainable growth and profitability. While facing challenges like market uncertainties, the company is leveraging opportunities through new product launches and cost efficiencies for future growth.

Tandem Diabetes Care surpasses Q3 sales expectations amidst market challenges

Tandem Diabetes Care's Q3 performance exceeded expectations with strong sales and positive margins, despite challenges in OUS distribution.
The company's focus on innovation, product success, and market positioning sets the stage for future growth opportunities.
Navigating disruptions and seizing growth potential through new product launches and market expansion are key priorities for Tandem.
Overall, Tandem remains optimistic about its trajectory and is actively pursuing strategic opportunities for growth.

Tandem Diabetes Care reports strong sales growth and strategic focus

Tandem Diabetes Care's Q4 2023 Earnings Call highlighted strong sales performance, positive customer feedback, and strategic focus on new product launches and operational efficiencies.
While facing challenges from unique events and increasing competition, Tandem is leveraging opportunities in U.S. and international markets, focusing on growth and innovation.
The company's outlook for 2024 includes a robust sales guidance, expansion plans, and a strategic approach to address market challenges and capitalize on emerging opportunities.

Tandem Diabetes Care reports robust Q1 sales growth and international expansion

Tandem Diabetes Care's Q1 2024 earnings call highlighted strong sales growth, successful product launches, and innovation in AID systems, with a focus on maintaining pricing and expanding internationally.
Challenges include pricing strategies, monitoring Mobi's impact, and navigating competitive OUS markets, while opportunities lie in market expansion, health outcome studies validation, and improving access and affordability.
Overall, Tandem's performance reflects a strategic approach to growth through product innovation, market expansion, and a focus on enhancing access and affordability in the diabetes care market.

Tandem Diabetes Care (TNDM) posts strong Q2 results, raises 2024 guidance

Tandem Diabetes Care (TNDM) reported robust Q2 2024 performance with sales growth, improved gross margin, and raised sales guidance. The company's focus on new products and commercial excellence positions it well for future growth.

Tandem Diabetes Care achieves record sales and positive cash flow

Tandem Diabetes Care delivered a strong performance in Q3 2024, marked by record sales and positive free cash flow. The company's focus on innovation, market awareness, and customer retention are key strengths. While facing challenges in a competitive market, Tandem Diabetes Care is well-positioned to capitalize on growth opportunities in 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its products include Tandem Mobi System and t:slim X2 Insulin Pump. The company was founded by Paul M. DiPerna on January 27, 2006, and is headquartered in San Diego, CA.

Tandem Diabetes' (TNDM) t:slim X2 is the first AID system in the world to feature Dexcom's most advanced CGM technology.

Tandem Diabetes (TNDM) Launches Dexcom G7 Integrated t:slim X2

SAN DIEGO--(BUSINESS WIRE)---- $TNDM #diabetes--Tandem Diabetes Care today announced the launch of updated t:slim X2™ insulin pump software with Dexcom G7 CGM integration in the United States.

Tandem Diabetes Care Launches t:slim X2 Insulin Pump Software with Dexcom G7 CGM Integration in U.S.

Tandem Diabetes Care, Inc. (TNDM) reported earnings 30 days ago. What's next for the stock?

Why Is Tandem Diabetes Care, Inc. (TNDM) Up 33.2% Since Last Earnings Report?

LOS ANGELES, CA / ACCESSWIRE / November 7, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Tandem Diabetes Care, Inc. ("Tandem" or "the Company") (NASDAQ:TNDM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 3, 2022 and November 2, 2022, inclusive (the "Class Period"), are encouraged to contact the firm before November 7, 2023.

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Tandem Diabetes Care, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming November 7, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Tandem Diabetes Care, Inc. (“Tandem” or the “Company”) (NASDAQ: TNDM) securities between August 3, 2022 and November 2, 2022, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On November 2, 2022, Tandem revised its 2022 financ.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Tandem Diabetes Care, Inc. (TNDM)

NEW YORK , Nov. 6, 2023 /PRNewswire/ -- Attention Tandem Diabetes Care, Inc. ("Tandem") (NASDAQ: TNDM) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between August 3, 2022 and November 2, 2022. If you suffered a loss on your investment in Tandem, contact us about potential recovery by using the link below.

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Tandem Investors of a Lead Plaintiff Deadline of November 7, 2023

LOS ANGELES, CA / ACCESSWIRE / November 6, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Tandem Diabetes Care, Inc. ("Tandem" or "the Company") (NASDAQ:TNDM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 3, 2022 and November 2, 2022, inclusive (the "Class Period"), are encouraged to contact the firm before November 7, 2023.

FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Tandem Diabetes Care, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / November 3, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Tandem Diabetes Care, Inc. ("Tandem" or "the Company") (NASDAQ:TNDM) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 3, 2022 and November 2, 2022, inclusive (the "Class Period"), are encouraged to contact the firm before November 7, 2023.

FINAL DEADLINE TUESDAY: The Schall Law Firm Encourages Investors in Tandem Diabetes Care, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK , Nov. 3, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Tandem Diabetes Care, Inc. ("Tandem" or the "Company") (NASDAQ: TNDM). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tandem Diabetes Care, Inc. - TNDM

LOS ANGELES , Nov. 3, 2023 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Tandem Diabetes Care, Inc. ("Tandem" or the "Company") (NASDAQ: TNDM). Class Period: August 3, 2022 – November 2, 2022 Lead Plaintiff Deadline: November 7, 2023 If you wish to serve as lead plaintiff of the Tandem lawsuit, you can submit your contact information at www.glancylaw.com/cases/Tandem-Diabetes-Care-Inc/.

TNDM Investors Have Opportunity to Lead Tandem Diabetes Care, Inc. Securities Fraud Lawsuit

LOS ANGELES, CA / ACCESSWIRE / November 3, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Tandem Diabetes Care, Inc. ("Tandem" or "the Company") (NASDAQ:TNDM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 3, 2022 and November 2, 2022, inclusive (the "Class Period"), are encouraged to contact the firm before November 7, 2023.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Tandem Diabetes Care, Inc. with Losses of $100,000 to Contact the Firm

Tandem Diabetes (TNDM) reports a higher-than-anticipated loss in the third quarter of 2023.

Tandem Diabetes (TNDM) Posts Wider Q3 Loss, Trims '23 Sales View

NEW YORK , Nov. 2, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Tandem Diabetes Care, Inc. ("Tandem" or the "Company") (NASDAQ: TNDM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Tandem investors who were adversely affected by alleged securities fraud between August 3, 2022 and November 2, 2022.

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Tandem Diabetes Care, Inc.(TNDM) Investors of a Class Action Lawsuit and Upcoming Deadline

LOS ANGELES, CA / ACCESSWIRE / November 2, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Tandem Diabetes Care, Inc. ("Tandem" or "the Company") (NASDAQ:TNDM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 3, 2022 and November 2, 2022, inclusive (the "Class Period"), are encouraged to contact the firm before November 7, 2023.

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Tandem Diabetes Care, Inc. with Losses of $100,000 to Contact the Firm

Tandem Diabetes Care, Inc. (NASDAQ:TNDM ) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Susan Morrison - EVP & Chief Administrative Officer John Sheridan - President, CEO & Director Leigh Vosseller - EVP, CFO & Treasurer Jordan Pinsker - VP & Medical Director Conference Call Participants Steven Lichtman - Oppenheimer Brooks O'Neil - Lake Street Capital Markets Matthew Taylor - Jefferies Matthew Miksic - Barclays Bank Joshua Jennings - TD Cowen Andrew Stafford - Piper Sandler & Co. Dane Reinhardt - Robert W. Baird & Co. Operator Thank you for standing by, and welcome to Tandem's Third Quarter 2023 Earnings Conference Call.

Tandem Diabetes Care, Inc. (TNDM) Q3 2023 Earnings Call Transcript

Although the revenue and EPS for Tandem Diabetes Care, Inc. (TNDM) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Compared to Estimates, Tandem Diabetes Care, Inc. (TNDM) Q3 Earnings: A Look at Key Metrics

SAN DIEGO--(BUSINESS WIRE)-- #TandemDiabetes--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Mark Novara as Executive Vice President and Chief Commercial Officer, effective November 13, 2023. Mr. Novara comes to Tandem with extensive global healthcare experience, having served in the diabetes, medical technology, and life sciences industries for nearly 25 years. “Mark is a strategic, global leader with a successful track r.

Tandem Diabetes Care Appoints Mark Novara as EVP and Chief Commercial Officer

SAN DIEGO--(BUSINESS WIRE)-- #TandemDiabetes--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2023 and updated its financial guidance for the year ending December 31, 2023. Third Quarter and Recent Highlights Worldwide installed base increased 11 percent to approximately 444,000 in-warranty customers compared to the third quarter 2022. Published prospective study data demonstrating the i.

Tandem Diabetes Care Announces Third Quarter 2023 Financial Results

LOS ANGELES, CA / ACCESSWIRE / October 31, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Tandem Diabetes Care, Inc. ("Tandem" or "the Company") (NASDAQ:TNDM) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 3, 2022 and November 2, 2022, inclusive (the "Class Period"), are encouraged to contact the firm before November 7, 2023.

DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Tandem Diabetes Care, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK , Oct. 31, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Tandem Diabetes Care, Inc.. Shareholders who purchased shares of TNDM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Tandem Diabetes Care, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 7, 2023 - (NASDAQ: TNDM)

NEW YORK , Oct. 30, 2023 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Tandem Diabetes Care, Inc. (NASDAQ: TNDM) between August 3, 2022 and November 2, 2022, both dates inclusive (the "Class Period"), of the important November 7, 2023 lead plaintiff deadline. SO WHAT: If you purchased Tandem securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

TNDM NOTICE: NATIONALLY RANKED ROSEN LAW FIRM Encourages Tandem Diabetes Care, Inc. Investors to Secure Counsel Before Important November 7 Deadline in Securities Class Action - TNDM

NEW YORK--(BUSINESS WIRE)---- $TNDM #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Tandem Diabetes Care, Inc. (“Tandem” or “the Company”) (NASDAQ: TNDM) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Tand.

TNDM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Tandem Diabetes Care, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

DexCom

Novo Nordisk

Insulet

Diabetes-device makers' stocks are breaking out of ‘GLP-1 jail' ahead of schedule, analysts say, after months of stock-market punishment based on fears that the popular obesity drugs would clobber the market for their products.

Diabetes stocks jump as obesity-drug recovery comes ahead of schedule, analysts say

AbbVie

AbbVie has good reasons for investors to take a close look at the stock, even though its best-selling drug recently lost patent exclusivity. Tandem Diabetes Care has plenty of room to increase sales, despite the macroeconomic challenges that have hindered it recently.

Got $1,000? These 2 Stocks Could Be Bargain Buys for 2023 and Beyond

NEW YORK , Oct. 23, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Tandem Diabetes Care, Inc. (NASDAQ: TNDM) between August 3, 2022 and November 2, 2022, both dates inclusive (the "Class Period"), of the important November 7, 2023 lead plaintiff deadline. SO WHAT: If you purchased Tandem securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A TOP RANKED LAW FIRM, Encourages Tandem Diabetes Care, Inc. Investors with Losses to Secure Counsel Before Important November 7 Deadline in Securities Class Action - TNDM

News for Tandem Diabetes Care Stock (TNDM)